Drug intelligence / Profile preview

avanafil + tamsulosin

Development stage
Unknown
Lead developer
VIVUS LLC
Modality
Small Molecules
Administration
Oral
01

Overview

**Avanafil + tamsulosin** is a combination of two small molecule drugs, avanafil, a phosphodiesterase type 5 (PDE5) inhibitor, and tamsulosin, an alpha-1 adrenergic receptor antagonist. Avanafil is indicated for the treatment of erectile dysfunction in men by increasing blood flow to the penis via inhibition of PDE5, which increases cyclic GMP, leading to smooth muscle relaxation in the corpus cavernosum. Tamsulosin is indicated primarily for the treatment of benign prostatic hyperplasia (BPH), where it works by blocking alpha-1 adrenergic receptors in the prostate and bladder neck, relaxing smooth muscle and improving urine flow. This combination is not marketed as a fixed-dose product but could be prescribed concomitantly in clinical practice. Coadministration requires caution due to the risk of additive hypotensive effects. Both drugs are taken orally, but they are not formulated as a fixed combination medication and there is no brand name for the combined use.

Brand names
FlomaxStendraJalyn
Other names
none
02

Targets

PDE5 (Phosphodiesterase 5A)ADRA1A (α1A)ADRA1D (α1D)CYP3A4 (Cytochrome P450 3A4)ADRA1B (α1B)

Beyond the preview

Go deeper on avanafil + tamsulosin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on avanafil + tamsulosin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call